Eye On Five

41 Things On Tap at OIS@ASCRS

41 Things On Tap at OIS@ASCRS

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging glaucoma therapies, the signature sessions on public market activity and “Masters of the Industry,” and a new panel on frontiers in femtosecond lasers. It’s all set for next Thursday, April…

Read More

What’s Happening in the Month Ahead: January 2018

Who Will be Making News Next Month?

pSivida Set to File 3-year Durasert NDA pSivida Corp. this month expects to file a New Drug Application with the Food and Drug Administration for its Durasert implant for three-year treatment of noninfectious uveitis. pSivida said that the FDA had granted its request for a small business waiver of the Prescription Drug User Fee Act…

Read More

Eye on Five – July Edition

OIS-Eye-On-Five

FDA Shoots Down Ocular Therapeutix’s Dextenza NDA The Food and Drug Administration (FDA) denied approval of Ocular Therapeutix’s resubmitted New Drug Application (NDA) for its Dextenza dexamethasone insert 0.4 mg for treatment of post-surgery ocular pain, citing ongoing concerns with manufacturing processes. Ocular Therapeutix first submitted the NDA in September 2015. The company filed an amendment…

Read More

Eye on Five – June Edition

OIS-Eye-On-Five

Novartis Reports Positive Phase III Results for RTH258 Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints of non-inferiority compared with Regeneron’s Eylea (aflibercept) for treatment of neovascular age-related macular degeneration (AMD). The results were from two Phase III studies, HAWK and HARRIER. HAWK also evaluated the 3-mg RTH258 formulation,…

Read More

Eye on Five – May Edition

OIS-Eye-On-Five

Alcon Launches Multifocal Toric IOL at ASCRS Alcon seized the platform of ASCRS 2017 to launch its AcrySof IQ ReSTOR +2.5 multifocal toric intraocular lens with ActiveFocus design. The IOL addresses both astigmatism and presbyopia at the time of cataract surgery. Shire Licenses Parion’s Dry Eye Agent Shire plc gained exclusive worldwide rights to develop…

Read More

Eye on Five – April Edition

OIS-Eye-On-Five

FDA Green Lights Allergan’s Tear Neurostimulator Allergan has been granted marketing authorization from the FDA for its TrueTear Intranasal Tear Neurostimulator. This is the only FDA-approved device designed to temporarily increase tear production during neurostimulation in adults with dry eye. TrueTear is a handheld stimulator with daily disposable tips that is inserted into the nasal cavity to…

Read More

Eye on Five – March Edition

OIS-Eye-On-Five

Ora Retained to Develop Cannabinoids for Eye Disease Ora Inc., a global contract research organization that specializes in ophthalmology, took the plunge into medical marijuana when AXIM Biotechnologies, a cannabinoid research and development firm, retained Ora to handle its product development and clinical trials for potential glaucoma and dry eye treatments utilizing cannabinoid-based therapeutics. Cannabinoids…

Read More

Eye on Five – February Edition

OIS-Eye-On-Five

Envisia Candidate Achieves Endpoint for IOP Lowering Envisia Therapeutics released Phase II results showing that its ENV515 candidate (travoprost XR) achieved clinically meaningful intraocular pressure (IOP) reduction over the 11-month trial period. ENV515 also demonstrated an IOP-lowering effect comparable to pre-study topical prostaglandin analogs and in-study topical timolol 0.5%. Envisa president Benjamin Yerxa presented the…

Read More

Eye on Five – January Edition

OIS-Eye-On-Five

Alcon Turnaround Has Novartis Exploring Spin-off With its Alcon turnaround plans on track, Novartis AG revealed it is exploring options that include spinning off Alcon or issuing an IPO for the eye-care unit – or even keeping it. Alcon lost $120 million in fourth-quarter 2016 and $132 million for the year versus a profit of…

Read More

Eye on Five – November Edition

OIS - Eye on Five

Trump Bump Fuels Biotech, Pharma Stocks Pharma and biotech stocks surged in the week after Donald Trump’s election, with the OIS Index jumping 13% and the NASDAQ Biotech Index surging 11.2%. The gains have since trailed off, but the latter index was still up 8% for November at month-end. Three anticipated policy changes have fueled…

Read More

Eye on Five – October Edition

OIS - Eye on Five

Sustained-Release Eylea Focus of Collaboration Ocular Therapeutix Inc. and Regeneron entered into a collaboration agreement to develop a sustained-release formulation of Regeneron’s Eylea (aflibercept), currently in preclinical development. Ocular Therapeutix is developing proprietary sustained-release hydrogel-based drug delivery depots for intravitreal injection that can be formulated with both small- and large-molecule agents. Ocular Therapeutix would receive…

Read More

Eye on Five – September Edition

OIS - Eye on Five

Johnson & Johnson Moves to Buy AMO The evolution of the ophthalmology sector continued with this month’s news that Johnson & Johnson Vision Care would pay $4.3 billion to acquire Abbott Medical Optics, the company’s ophthalmology surgery business. The deal – if closed – promises to bring a newly engaged and energized Johnson & Johnson into…

Read More